Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: Detection with a new neoepitope endopeptidase immunoassay

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 1, 2011, Pages 74-80

  Jones, Russell G A ^a   Liu, Yvonne ^a   Halls, Chris ^a   Thorpe, Susan J ^a   Longstaff, Colin ^a   Matejtschuk, Paul ^a   Sesardic, Dorothea ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Albumin; Botulinum; Neurotoxin; Protease; Toxin

Indexed keywords

ALANINE; ALPHA 2 ANTIPLASMIN; APROTININ; ARGININE; BOTULINUM TOXIN A; EPITOPE; HUMAN SERUM ALBUMIN; KALLIKREIN; PLASMIN; PREKALLIKREIN; PROTEINASE; RECOMBINANT PROTEIN; SODIUM CHLORIDE; TRYPSIN; ZINC;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; IMMUNOASSAY; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; REDUCTION;

ALBUMINS; BOTULINUM TOXINS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; EPITOPES; HUMANS; IMMUNOASSAY; NEUROTOXINS; PEPTIDES; PHENYLALANINE; SERUM ALBUMIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; TISSUE KALLIKREINS; TRANEXAMIC ACID; ZINC;

EID: 77957021055     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.08.013     Document Type: Article

References (33)

1. Truong D.D., Stenner A., Reichel G. Current clinical applications of botulinum toxin. Curr. Pharm. Des. 2009, 15:3671-3680.
2. Foster K.A., Adams E.J., Durose L., Cruttwell C.J., Marks E., Shone C.C., Chaddock J.A., Cox C.L., Heaton C., Sutton J.M., Wayne J., Alexander F.C., Rogers D.F. Re-engineering the target specificity of clostridial neurotoxins-a route to novel therapeutics. Neurotox. Res. 2006, 9:101-107.
3. Raina S., Missiakas D. Making and breaking disulfide bonds. Annu. Rev. Microbiol. 1997, 51:179-202.
4. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
5. Feener E.P., Shen W.C., Ryser H.J. Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. J. Biol. Chem. 1990, 265:18780-18785.
6. Williamson L.C., Halpern J.L., Montecucco C., Brown J.E., Neale E.A. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25kDa. J. Biol. Chem. 1996, 271:7694-7699.
7. Jones R.G.A., Liu Y., Sesardic D. New highly specific botulinum type C1 endopeptidase immunoassays utilising SNAP25 or syntaxin substrates. J. Immunol. Methods 2009, 343:21-27.
8. Jones R.G.A., Ochiai M., Liu Y., Ekong T., Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J. Immunol. Methods 2008, 329:92-101.
9. Hunt T., Clarke K., Rupp D., Shimizu G., Tam K. Secondary cleavage of a fluorescently labeled SNAP-25 substrate by Xeomin drug product. Toxicon 2008, 51(Supplement 1):13.
10. Brin M.F. Basic and clinical aspects of Botox. Toxicon 2009, 54:676-682.
11. Sesardic D., Leung T., Gaines D.R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 2003, 31:265-276.
12. Finney D.J. Statistical Method in Biological Assay 1978, Charles Griffin, London.
13. Snape T.J., Griffith D., Vallet L., Wesley E.D. The assay of prekallikrein activator in human blood products. Dev. Biol. Stand. 1979, 44:115-120.
14. Prekallikrein Activator, Ph. Eur., Council of Europe, Strasbourg, France, 2008.
15. Longstaff C., Behr-Gross M.E., Daas A., Lackner F. An international collaborative study to replace the 1st international standard for prekallikrein activator. Vox Sang. 2005, 88:143-151.
16. Ahmed H. Principles and Reactions of Protein Extraction, Purification, and Characterization 2004, CRC Press.
17. Tayeh N., Rungassamy T., Albani J.R. Fluorescence spectral resolution of tryptophan residues in bovine and human serum albumins. J. Pharm. Biomed. Anal. 2009, 50:107-116.
18. Watanabe H., Tanase S., Nakajou K., Maruyama T., Kragh-Hansen U., Otagiri M. Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem. J. 2000, 349:813-819.
19. Sakurai Y., Ma S.F., Watanabe H., Yamaotsu N., Hirono S., Kurono Y., Kragh-Hansen U., Otagiri M. Esterase-like activity of serum albumin: characterization of its structural chemistry using p-nitrophenyl esters as substrates. Pharm. Res. 2004, 21:285-292.
20. Cordova J., Ryan J.D., Boonyaratanakornkit B.B., Clark D.S. Esterase activity of bovine serum albumin up to 160 degrees C: a new benchmark for biocatalysis. Enzyme Microb. Technol. 2008, 42:278-283.
21. Zilg H., Schneider H., Seiler F.R. Molecular aspects of albumin functions: indications for its use in plasma substitution. Dev. Biol. Stand. 1980, 48:31-42.
22. Gundry R.L., Fu Q., Jelinek C.A., Van Eyk J.E., Cotter R.J. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomic. Clin. Appl. 2007, 1:73-88.
23. Turner P.J., Young I.F., Marley P.B., Herrington R.W., Schiff P. Albumin solutions-their production and quality control. Dev. Biol. Stand. 1987, 67:119-127.
24. Alving B.M., Hojima Y., Pisano J.J., Mason B.L., Buckingham R.E., Mozen M.M., Finlayson J.S. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. New Engl. J. Med. 1978, 299:66-70.
25. Matejtschuk P., Dash C.H., Gascoigne E.W. Production of human albumin solution: a continually developing colloid. Br. J. Anaesth. 2000, 85:887-895.
26. Che Y., Wilson F.J., Bertolini J., Schiff P., Maher D.W. Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988-2005. Crit. Care Resusc. 2006, 8:334-338.
27. Chung D.W., Fujikawa K., McMullen B.A., Davie E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986, 25:2410-2417.
28. Barron M.E, Wilkes M.M., Navickis R.J. A systematic review of the comparative safety of colloids. Arch. Surg. 2004, 139:552-563.
29. Goodnough M.C., Johnson E.A. Stabilization of botulinum toxin type A during lyophilization. Appl. Environ. Microbiol. 1992, 58:3426-3428.
30. Grein S., Mander G.J., Taylor H.V. Xeomin is stable without refrigeration: complexing proteins are not required for stability of botulinum neurotoxin type A preparations. Toxicon 2008, 51(Supplement 1):13.
31. Frevert J. Xeomin is free from complexing proteins. Toxicon 2009, 54:697-701.
32. Uriel J., Trojan J., Dubouch P., Pineiro A. Intracellular alpha-fetoprotein and albumin in the developing nervous system of the baboon. Pathol. Biol. (Paris) 1982, 30:79-83.
33. Hooper C., Taylor D.L., Pocock J.M. Pure albumin is a potent trigger of calcium signalling and proliferation in microglia but not macrophages or astrocytes. J. Neurochem. 2005, 92:1363-1376.